RSV vaccines prove effective as US tightens access restrictions
TL;DR
New data reinforce that RSV vaccines dramatically reduce hospitalizations, with pregnancy-based protection around 70% and newborn monoclonal antibodies about 81%, and four JAMA studies confirm declines. Despite this, the administration’s restrictions to high‑risk infants could raise RSV hospitalizations and complicate vaccine logistics in a fragmented US system. Safety reviews are underway after trial deaths, though officials say there’s no proven vaccine link, and many countries rely on universal prenatal vaccination.
- Evidence shows benefit of RSV vaccines as Trump officials push restrictions The Guardian
- Infants receiving nirsevimab fare better against RSV compared to those with maternal vaccination Medical Xpress
- Danish Medicines Council Partially Recommends Beyfortus for RSV Prevention NAVLIN DAILY
- Nirsevimab Effectively Reduces RSV Infection and Hospitalizations The Hospitalist
- Nirsevimab May Top Maternal Shot for Infants' RSV Prevention Medscape
Want the full story? Read the original reporting
Read on The Guardian